Schouten Jan S A G

Römkens Hellen C S, Beckers Henny J M, Schouten Jan S A G, Berendschot Tos T J M, Webers Carroll A B

Combined provocative testing for narrow angles showed no clinical significance for predicting angle closure disease or related damage, making it unhelpful for early diagnosis.

Mokhles Palwasha, van Gorcom Luuk, Schouten Jan S A G, Berendschot Tos T J M, Beckers Henny J M, Webers Carroll A B

Studying deceased glaucoma patients, researchers found 30.5% had bilateral visual impairment. Glaucoma contributed, but other eye diseases, especially retinal/macular, were also major causes. Comprehensive care beyond IOP is crucial.

Römkens Hellen C S, Beckers Henny J M, Schouten Jan S A G, Nuijts Rudy M M A, Berendschot Tos T J M, Breusegem Christophe M et al.

Römkens Hellen C S, Beckers Henny J M, Schouten Jan S A G, Nuijts Rudy M M A, Berendschot Tos T J M, Breusegem Christophe M et al.

Römkens Hellen C S, Beckers Henny J M, Schouten Jan S A G, Nuijts Rudy M M A, Berendschot Tos T J M, Breusegem Christophe M et al.

Römkens Hellen C S, Beckers Henny J M, Schouten Jan S A G, Nuijts Rudy M M A, Berendschot Tos T J M, Breusegem Christophe M et al.

Early cataract surgery after acute angle closure significantly lowered eye pressure, reduced glaucoma medications, and improved vision, offering a promising treatment for these patients.

de Crom Ronald M P C, Webers Carroll A B, van Kooten-Noordzij Marina A W, Michiels Agnes C, Schouten Jan S A G, Berendschot Tos T J M et al.

This study found wind instrument playing temporarily raises eye pressure, but similar or higher pressure spikes occur during other daily activities and sleep. These pressure peaks may be clinically relevant for glaucoma progression.

Mokhles Palwasha, Schouten Jan S A G, Beckers Henny J M, Azuara-Blanco Augusto, Tuulonen Anja, Webers Carroll A B

This review found treated glaucoma patients still experience significant end-of-life blindness (up to 24% unilateral, 10% bilateral), often linked to advanced disease, IOP fluctuations, and poor compliance, highlighting prevention needs.

Ernest Paul J G, Schouten Jan S A G, Beckers Henny J M, Hendrikse Fred, Prins Martin H, Webers Carroll A B

A model using age, baseline IOP, and visual field status predicted glaucoma progression, but explained little variance. It could help identify high-risk patients for more intensive treatment.

van Gestel Aukje, Webers Carroll A B, Beckers Henny J M, Peeters Andrea, Severens Johan L, Schouten Jan S A G

This study modeled ocular hypertension, finding the 15-year risk of unilateral blindness is under 10% for both treated and untreated patients, informing clinical management decisions.

van Gestel Aukje, Schouten Jan S A G, Beckers Henny J M, Severens Johan L, Hendrikse Fred, Webers Carroll A B

Studying ocular hypertension, early pressure-lowering treatment was found to be more effective and cheaper long-term than delayed treatment, making it a dominant, cost-effective strategy.

Ernest Paul J G, Busch Michiel J W M, Webers Carroll A B, Beckers Henny J M, Hendrikse Fred, Prins Martin H et al.

This study found 26% of open-angle glaucoma patients had end-of-life visual impairment, often linked to severe initial loss. In glaucoma suspects, impairment was lower and due to other eye conditions.

Beckers Henny J M, Webers Carroll A B, Busch Michiel J W M, Brink Hendrik M A, Colen Thomas P, Schouten Jan S A G

Neither patient education nor a drop guider improved glaucoma adherence or IOP. "Drug holidays" led to higher IOP, highlighting the risk of inconsistent medication use.

Ernest Paul J G, Schouten Jan S A G, Beckers Henny J M, Hendrikse Fred, Prins Martin H, Webers Carroll A B

This review found 301 visual field progression methods, but evidence for their validity and reproducibility is limited. Selecting from a few validated methods, especially those quantifying progression rates, is crucial for clinical decision-making.

Peeters Andrea, Schouten Jan S A G, Severens Johan L, Hendrikse Fred, Prins Martin H, Webers Carroll A B

This study found starting ocular hypertension treatment with timolol was more cost-effective than latanoprost for preventing blindness, due to latanoprost's higher cost.

Ernest Paul J G, Viechtbauer Wolfgang, Schouten Jan S A G, Beckers Henny J M, Hendrikse Fred, Prins Martin H et al.

This study found glaucoma visual field progression rates vary widely (2-62%) depending on the assessment method, follow-up time, and baseline visual field loss, highlighting method-specific reporting is crucial.

Peeters Andrea, Webers Carroll A B, Prins Martin H, Hendrikse Fred, Schouten Jan S A G

Simulating initial timolol vs. latanoprost for ocular hypertension showed both strategies similarly lowered IOP and prevented blindness, suggesting initial drug choice has minimal long-term impact due to target-pressure guided adjustments.

Webers Carroll A B, Beckers Henny J M, Zeegers Maurice P, Nuijts Rudy M M A, Hendrikse Fred, Schouten Jan S A G

This meta-analysis found adding PGAs to β-blockers significantly lowers IOP. Concomitant use yielded more reduction than fixed combinations, with evening dosing showing largest peak effects, guiding glaucoma treatment strategies.

Peeters Andrea, Webers Carroll A B, Prins Martin H, Zeegers Maurice P, Hendrikse Fred, Schouten Jan S A G

IOP reduction significantly lowers glaucoma conversion risk in ocular hypertension, with greater IOP lowering yielding more protection, emphasizing its clinical importance.

Olthoff Christine M G, Hoevenaars Juliette G M M, van den Borne Bart W, Webers Carroll A B, Schouten Jan S A G

27% of Dutch glaucoma patients reported non-adherence, often due to forgetfulness or application difficulties. Addressing these issues with aids or better delivery systems could improve adherence, delaying advanced therapies.

Hoevenaars Juliette G M M, Schouten Jan S A G, van den Borne Bart, Beckers Henny J M, Webers Carroll A B

Studying glaucoma patients, researchers found improving knowledge alone is unlikely to significantly boost medication compliance. Interventions targeting attitude and discipline may be more effective.

Beckers Henny J M, Schouten Jan S A G, Webers Carroll A B, van der Valk Rikkert, Hendrikse Fred

This study found most glaucoma patients are satisfied with their eye drops, experiencing low side effects and infrequent discontinuation, with common medications showing similar tolerability.

van der Valk Rikkert, Webers Carroll A B, Hendrikse Fred, de Vogel Stefan C, Prins Martin H, Schouten Jan S A G

This study found timolol and latanoprost provide similar IOP reduction in practice. Importantly, routine patient data, beyond baseline IOP, cannot reliably predict individual treatment response for glaucoma management.

Webers Carroll A B, van der Valk Rikkert, Schouten Jan S A G, Zeegers Maurice P, Prins Martin H, Hendrikse Fred

Adding dorzolamide or latanoprost to timolol significantly lowers intraocular pressure further, with latanoprost showing a greater effect, providing effective combination therapy for glaucoma.

van der Valk Rikkert, Schouten Jan S A G, Webers Carroll A B, Hendrikse Fred, Prins Martin H

New glaucoma drugs introduced in 1999 shifted treatment patterns, leading to more combination therapy and significantly lower achieved IOPs for patients, improving glaucoma control.